ATE295731T1 - Olanzapine zur behandlung von drogenmissbrauch - Google Patents

Olanzapine zur behandlung von drogenmissbrauch

Info

Publication number
ATE295731T1
ATE295731T1 AT97908871T AT97908871T ATE295731T1 AT E295731 T1 ATE295731 T1 AT E295731T1 AT 97908871 T AT97908871 T AT 97908871T AT 97908871 T AT97908871 T AT 97908871T AT E295731 T1 ATE295731 T1 AT E295731T1
Authority
AT
Austria
Prior art keywords
olnzapine
treatment
drug abuse
olanzapine
administering
Prior art date
Application number
AT97908871T
Other languages
English (en)
Inventor
Charles M Beasley Jr
Kurt Rasmussen
Gary D Tollefson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9606615.4A external-priority patent/GB9606615D0/en
Priority claimed from GBGB9606617.0A external-priority patent/GB9606617D0/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE295731T1 publication Critical patent/ATE295731T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
AT97908871T 1996-03-11 1997-03-10 Olanzapine zur behandlung von drogenmissbrauch ATE295731T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1316096P 1996-03-11 1996-03-11
US1316196P 1996-03-11 1996-03-11
GBGB9606615.4A GB9606615D0 (en) 1996-03-29 1996-03-29 Method for treating alcohol addiction
GBGB9606617.0A GB9606617D0 (en) 1996-03-29 1996-03-29 Method for treating substance abuse
PCT/US1997/003404 WO1997033586A1 (en) 1996-03-11 1997-03-10 Method for treating substance abuse

Publications (1)

Publication Number Publication Date
ATE295731T1 true ATE295731T1 (de) 2005-06-15

Family

ID=27451428

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97908871T ATE295731T1 (de) 1996-03-11 1997-03-10 Olanzapine zur behandlung von drogenmissbrauch

Country Status (15)

Country Link
EP (1) EP1007050B1 (de)
JP (1) JP2000517287A (de)
KR (1) KR19990087714A (de)
CN (1) CN1213308A (de)
AT (1) ATE295731T1 (de)
BR (1) BR9708037A (de)
CA (1) CA2248738A1 (de)
CZ (1) CZ290398A3 (de)
DE (1) DE69733321D1 (de)
IL (1) IL126158A0 (de)
NO (1) NO984196L (de)
NZ (1) NZ331845A (de)
PL (1) PL328924A1 (de)
TR (1) TR199801801T2 (de)
WO (1) WO1997033586A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1133300E (pt) 1998-11-23 2005-04-29 Sepracor Inc Composicoes de desmetilolanzapina e metodos
ES2211205T3 (es) * 1998-11-23 2004-07-01 Sepracor Inc. Composiciones farmaceuticas que contienen olanzapina-n-oxido.
US6174882B1 (en) 1998-11-23 2001-01-16 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
MXPA03006251A (es) * 2001-01-12 2004-10-15 Innovation Ventures Llc Composicion a base de carbon vegetal activado y metodo para reducir sintomas de resaca asociados con el consumo de bebidas que contienen alcohol.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5605911A (en) * 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
US5696115A (en) * 1995-04-21 1997-12-09 Eli Lilly And Company Method for treating nicotine withdrawal

Also Published As

Publication number Publication date
AU725940B2 (en) 2000-10-26
WO1997033586A1 (en) 1997-09-18
CA2248738A1 (en) 1997-09-18
EP1007050A4 (de) 2000-06-14
EP1007050B1 (de) 2005-05-18
AU2067297A (en) 1997-10-01
CN1213308A (zh) 1999-04-07
NO984196D0 (no) 1998-09-11
PL328924A1 (en) 1999-03-01
JP2000517287A (ja) 2000-12-26
KR19990087714A (ko) 1999-12-27
BR9708037A (pt) 1999-07-27
NO984196L (no) 1998-11-03
CZ290398A3 (cs) 1999-10-13
TR199801801T2 (xx) 1998-12-21
EP1007050A1 (de) 2000-06-14
DE69733321D1 (de) 2005-06-23
IL126158A0 (en) 1999-05-09
NZ331845A (en) 2000-09-29

Similar Documents

Publication Publication Date Title
DE69805973T2 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
ATE207352T1 (de) Nicht-allosterische gaba a agonisten zur behandlung von schlafstörungen
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
DE69620691T2 (de) Therapeutisches Mittel zur Behandlung der Hypercholesterinämie
ATE222109T1 (de) Kombiniertes therapeutisches verfahren zur behandlung von hyperproliferativen krankheiten
YU42298A (sh) Upotreba olanzapina za pripremanje leka korisnog kod akutnog bola
DE69829217D1 (de) Vorrichtung zur therapeutischen behandlung von blutgefässen
ATA901396A (de) Verwendung von melatonin zur behandlung von an medikamentensucht leidenden patienten
ATE295731T1 (de) Olanzapine zur behandlung von drogenmissbrauch
ATE251462T1 (de) Verfahren zur behandlung von narbengewebe
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
NO984198L (no) FremgangsmÕte for behandling av aggresjon
EA199800820A1 (ru) Способ лечения злоупотребления лекарственными средствами
DE69800906D1 (de) Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie
DE60122781D1 (de) Neue therapeutische verwendung eines derivates von thienylcyclohexylamine zur behandlung von schmerzen
DE69430807D1 (de) Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen
DE9411818U1 (de) Medizinisches Gerät zur Behandlung von rheumatischen Schmerzen
EA199800818A1 (ru) Способ лечения бессонницы
RU97110384A (ru) Способ лечения вибрационной болезни
YU40198A (sh) Postupak za tretiranje zavisnosti od supstance
ATA51896A (de) Pharmazeutisches präparat zur behandlung von blutgerinnungsstörungen
ATA17797A (de) Pharmazeutisches präparat zur behandlung von blutgerinnungsstörungen
DE69828553D1 (de) Gerät zur behandlung von harnwegs- und anderen körperstenosen
DE60030593D1 (de) Labdan-enthaltende arzneiformulierungen zur behandlung von tumoren oder leukämien

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties